Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia.
- Author:
Xiao-Yan CHEN
1
;
Chao LIU
;
Wen-Qi WU
;
Ao-Li ZHANG
;
Li-Peng LIU
;
Yang LAN
;
Yu-Li CAI
;
Min RUAN
;
Xiao-Fan ZHU
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. xfzhu@ihcams.ac.cn.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Child;
Humans;
Leukemia, Myeloid, Acute;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(5):466-472
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy of the CAMS-2005 and CAMS-2009 regimens in treating children with non-core binding factor acute myeloid leukemia (non-CBF AML) and to study the prognosis factors.
METHODS:A total of 161 children who were initially diagnosed with non-CBF AML from April 2005 to December 2015 were enrolled as study subjects, and were divided into a CAMS-2005 regimen group (n=52) and a CAMS-2009 regimen group (n=109) according to the chemotherapy regimen provided. The efficacy was retrospectively compared between the two groups.
RESULTS:The complete remission (CR) rate at the first course of treatment was higher in the CAMS-2009 regimen group than that in the CMAS-2005 regimen group (63.3% vs 46.2%; P<0.05). There were no significant differences between the two groups in treatment-related mortality rate (11.9% vs 17.3%), recurrence rate (27.5% vs 28.8%), and three-year overall survival (OS) rate (44%±5% vs 28%±6%) (P>0.05). Children who achieved CR at the first course of treatment had significantly higher OS and event-free survival rates than those who did not achieved CR (P<0.01).
CONCLUSIONS:The CAMS-2009 regimen is superior to the CAMS-2005 regimen in improving the CR rate in children with non-CBF AML after induction treatment. Whether CR is achieved at the first course of treatment can affect the OS rate of children with non-CBF AML.
